Sustainability and "Green" Excipients
In 2026, the biopharma industry is under intense pressure to meet ESG (Environmental, Social, and Governance) standards. This has led to a surge in Bio-Derived and Plant-Based Excipients.
Leading manufacturers are replacing petrochemical-based polymers with sustainable alternatives derived from non-GMO plant sources. These "Green Excipients" must still meet ultra-high purity standards—specifically low-endotoxin levels—to ensure they don't cause immune reactions in patients. This shift is not just environmental; plant-based oligosaccharides are often proving more stable than their synthetic counterparts in 2026 clinical trials.
3 Views